Chromosome 18 suppresses XXXX @entity3 .

@entity1 @entity263 @entity19 @entity5 @entity3
Loss of heterozygosity and allelic imbalance data has shown that there are two distinct regions of loss on chromosome 18q associated with the progression of @entity263 (CaP). To investigate the functional significance of chromosome 18q loci in CaP, we utilized the technique of microcell-mediated chromosome transfer to introduce an intact chromosome 18 into the @entity1 @entity263 cell line, PC-3. Three of the resulting hybrid lines were compared to the PC-3 cells in vitro and in vivo. The hybrid cell lines, containing an intact copy of the introduced chromosome 18, exhibited a substantial reduction in anchorage-dependent and independent growth in vitro. These hybrid cell lines also made smaller @entity5 in @entity19 following subcutaneous injection compared to PC-3 cells. Because @entity5 growth was not completely eliminated by introduction of chromosome 18, we assessed the ability of the hybrids to metastasize to bone after intra-cardiac inoculation in a nude @entity19 model. @entity19 inoculated with PC-3 hybrids containing intact copies of chromosome 18 had significantly fewer bone @entity3 and dramatically improved survival compared to PC-3 cells. In addition, the introduction of chromosome 18 significantly reduced @entity5 burden in extraskeletal sites. This was not because of differences in growth rates because @entity19 bearing hybrids were monitored for @entity3 over twice as long as @entity19 bearing PC-3 cells. Taken together, these data suggest that chromosome 18 has a functional role in CaP to suppress growth and @entity3 . Identification of the responsible gene(s) may lead to molecular targets for drug discovery.
